Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meglumine ginkgolide injection
- Development stage
- Unknown
- Lead developer
- Lianyungang Kanion
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Meglumine ginkgolide injection (brand name Yousaijin) is a botanical extract developed by Jiangsu Kanion Pharmaceutical and China Pharmaceutical University. It is composed of ginkgolides A, B, and K, which are active diterpene lactones extracted from Ginkgo biloba leaves. The drug acts as a potent and selective antagonist of the platelet-activating factor receptor (PAFR), thereby inhibiting PAF-induced platelet aggregation, reducing neuroinflammation, and protecting the blood-brain barrier. It is approved in China for the treatment of mild-to-moderate cerebral infarction (ischemic stroke) during the recovery phase and is undergoing Phase II clinical evaluation for acute ischemic stroke.
- Brand names
- 尤赛金YosaijinYousaijin
- Other names
- ginkgo diterpene lactone meglumine injectionditerpene ginkgolides meglumine injection银杏二萜内酯葡胺注射液YinxingErtieneizhiPu'an ZhusheyeDGMIGDLMIGDLI
02
Targets
PTAFR (Platelet-activating factor receptor)
Beyond the preview
Go deeper on meglumine ginkgolide injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meglumine ginkgolide injection.